Nervous System Diseases

1,005 trials 421 recruiting

Filter these 1,005 trials by phase, country and sponsor.

Open in Search →

Effects of NT-0796 in Healthy Volunteers and Patients with Parkinson’s Disease Ended

2023-503203-29-00 Parkinson's Disease 3 2023-04-12
A DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, PHASE I STUDY TO ASSESS THE SAFETY, TOLERABILITY, AND PHARMACOKINETICS OF SINGLE ANDMULTIPLE… Ended

2024-517955-10-00 Healthy volunteers 1 2023-04-05
Protocol Lay Person Short Title: A Trial of the Safety and Efficacy of Flexible Doses of SEP-363856 as Adjunctive Therapy in the Treatment o… Ended

2022-500538-27-00 Adjunctive therapy to antidepressants for the treatmen 10 2023-03-30
Selän alueen poikkeava aktiivisuus servikaalisessa dystoniassa Ended

2024-517068-43-00 Servikaalinen dystonia, jossa poikkeavaa lihasaktiivisu 6 2023-03-27
AmaNtadine for NeuroenhancEment in acutE patients Study - A prospective pilot proof of concept phase IIb study in intensive and intermediate… Ended

2024-512333-33-00 unresponsive wakefulness syndrome not otherwise explain 4 2023-03-21
C4951004 - BHV3000-406: A Phase 4, Randomized, Double-blind Placebo Controlled, Efficacy and Tolerability Trial of Rimegepant for the Acute … Ended

2024-513269-37-00 Migraine attacks with or without aura 6 2023-03-14
C4951012 - BHV3000-407: A Phase 4, Randomized, Double-blind, Placebo controlled Study to Evaluate the Efficacy and Tolerability of Rimegepan… Ended

2024-513270-21-00 migraine headaches with or without aura 6 2023-03-14
Phase IIa Aqueous Afamelanotide Solution Stroke Study Ended

2022-500919-40-01 Arterial Ischaemic Stroke (AIS) 4 2023-03-10
A study to find out if daridorexant is safe and efficacious to treat insomnia in patients with insomnia and comorbid nocturia Ended

2022-501246-30-00 Insomnia Disorder 6 2023-03-08
Investigation of treating chronic fatigue syndrome after COVID with pharmacotherapy (pregabalin) or complex rehabilitation Ended

2024-516174-30-01 Chronic fatigue syndrome associated with post-COVID syn 4 2023-03-08
A Randomized, Open-Label, Single-Dose, Parallel-Group Study to Evaluate the Relative Bioavailability of LY03010 versus Xeplion® after Intram… Ended

2022-502179-48-00 Schizophrenia 2 2023-02-23
A Phase 2a/2b Randomized, Placebo-Controlled Clinical Study to Evaluate the Safety and Efficacy of MK-1942 as Adjunctive Therapy in Particip… Ended

2023-504017-79-00 Treatment of AD dementia 4 2023-02-14
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Parallel Study to Assess the Efficacy, Safety, Tolerability, PK, and Biomarker Effe… Ended

2023-510317-26-00 Amyotrophic Lateral Sclerosis 4 2023-02-07
Phase 3 Study to Assess Efficacy and Safety of Batoclimab as Induction and Maintenance Therapy in Adult Participants with Generalized Myasth… Ended

2024-512258-91-00 Generalized Myasthenia Gravis (gMG) 5 2023-02-03
A study investigating the safety, tolerability, absorption, excretion and effects of a new drug for the treatment of epilepsy. Ended

2022-502638-17-00 Epilepsy 3 2023-02-03
STRIDES - A Clinical Research Study of an Investigational New Drug to Treat Spinocerebellar Ataxia Ended

2022-501004-10-00 Spinocerebellar Ataxia type-3 (SCA3) 10 2023-01-30
A clinical study to learn whether a new drug, TPN-101, is safe when given to AGS patients Ended

2024-511176-32-00 Aicardi-Goutières Syndrome (AGS) 4 2023-01-27
Glenzocimab for REperfusion in the setting of Endovascular therapy for brain infarctioN Ended

2024-514352-32-00 Acute ischemic stroke 10 2023-01-03
An extension of the orchestra (PD0053) study to learn how safe minzasolmin is and if it works long-term in participants with Parkinson’s dis… Ended

2022-500424-30-00 Parkinson’s disease 4 2022-12-28
Bioequivalence of Oxazepam 50 mg Orodispersible Tablets Versus Seresta® 50 mg Tablets in Healthy Subjects. Ended

2022-501135-16-00 No medical condition is being investigated. This is a c 2 2022-12-26
A Phase 2 double-blind, randomized, placebo-controlled study evaluating the effect of SAR443820 on serum neurofilament levels in participant… Ended

2023-509078-45-00 Multiple sclerosis 4 2022-12-19
A study to find out which dose of daridorexant is safe and effective to treat insomnia in children and adolescents 10 to <18 years old Ended

2024-513885-20-00 Insomnia Disorder 4 2022-12-05
A Phase 2b, multicenter, randomized, double-blind, placebo-controlled study to determine the efficacy and safety of BIIB122 in participants … Ended

2023-505645-12-00 Parkinson's Disease 4 2022-11-28
A Study to evaluate Efficacy, Safety, Tolerability and Effects of TAK-341 in the human body in patients with Multiple System Atrophy Ended

2023-509876-40-00 Multiple System Atrophy 4 2022-11-22